Why the study?
Several new drugs to reduce ischemic complications in stable ischemic heart disease have been approved since 2014.
This review provides an update on the clinical management of stable ischemic heart disease, highlighting new pharmacological therapies approved since 2014.
May inform SIHD management updates with post-2014 agents; extends 2014 review while leaving comparative efficacy open.
Stable ischemic heart disease (SIHD) is a leading cause of death in the United States and many other countries. The defining pathobiology is an imbalance between the metabolic demands of the myocardium and its oxygen supply, which most often results from coronary artery atherosclerosis. The classic presenting symptom of SIHD is angina, but clinical presentation varies greatly among patients. Since the last In the Clinic on SIHD in 2014, several new drugs have been approved to reduce ischemic complications, such as myocardial infarction and congestive heart failure.
No takes yet. Share an insight, caveat, or question.
Katz et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: